K27.F KODIAK SCIENCES DL-0001

Healthcare Biotechnology Frankfurt Exchange
99.72 EUR
Close of Nov 12, 2026
15.61 100.40
Market cap
EUR 6.27B
P/E
-
P/B
112.77x
ROE
-405.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is K27.F undervalued?

Graham number

The Graham number of KODIAK SCIENCES DL-0001 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KODIAK SCIENCES DL-0001 fundamental analysis

No fundamental analysis for KODIAK SCIENCES DL-0001 yet.

KODIAK SCIENCES DL-0001 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KODIAK SCIENCES DL-0001

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-relat…

Full company profile